Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis - MAHALE

Study identifier:D325BC00001

ClinicalTrials.gov identifier:NCT05006573

EudraCT identifier:2020-004068-24

CTIS identifier:N/A

Study Complete

Official Title

A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 52 Week, Phase III Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients With Non-Cystic Fibrosis Bronchiectasis (MAHALE)

Medical condition

Non-cystic Fibrosis Bronchiectasis

Phase

Phase 3

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

100

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 21 Jul 2021
Primary Completion Date: 16 Apr 2024
Study Completion Date: 16 Apr 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Apr 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria